-
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
-
Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
